Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SMS-oncology Announces Changes to the Management Team

Published: Monday, February 04, 2013
Last Updated: Monday, February 04, 2013
Bookmark and Share
Specialized Medical Services-oncology BV announced its management team has been changed and expanded to five executive members.

Members are: Edwin Klumper (Chief Executive Officer, CEO), Philine van den Tol (Chief Operating Officer, COO), Eric van der Putten (Chief Business Development Officer, CBDO), Wouter Wijker (Managing Director Biometrics Unit), and Raymond Hoffmans (Director Consultancy).

The new CEO Edwin Klumper will succeed Eric van der Putten who will take on the position of CBDO. In his new role Eric will be responsible for driving new business opportunities and growing our client base. Edwin Klumper stated: "All credits go to Eric van der Putten who has been the driving force into building a fully GCP compliant CRO from scratch within five years that has resulted into ISO 9001:2008 certification in 2012. Our clients will benefit discussing their new cancer studies with Eric who brings to the table 30+ years of experience in running phase I and II cancer trials in close collaboration with the top tier of oncologists. His experience and operational insights will be of great value to our clients in achieving their objectives.”

Philine van den Tol has been promoted to the position of COO. With her no-nonsense and can-do attitude Philine motivates and leads by example the operational staff of SMS-oncology. She knows what it takes to run multiple multicenter cancer studies from her past experience as project manager for the Dutch Breast Cancer Trialists’ Group. The Management Team is completed by Raymond Hoffmans (Director Consultancy) and Wouter Wijker (Managing Director Biometrics Unit).

We thank Erik Leferink who has been leading in the foundation of SMS-oncology. Erik will hand over his business development responsibilities to Eric van der Putten. As a serial entrepreneur Erik will reallocate his time to grow new ventures that he has recently established. Erik will remain active as a shareholder of SMS-oncology.

“These changes reflect our steady growth and mark our next step”, said Edwin Klumper. “After 5 years of serving over 50 clients, building a highly motivated and oncology experienced staff, expanding our trial base across Europe, collaborating with top oncology centers, we are ready for our next step and ambition to become a European premier oncology CRO. It is a privilege to lead such a good team and serve our clients to jointly improve cancer treatment by developing new drugs that are desperately needed by so many patients".


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
How Baby’s Genes Influence Birth Weight And Later Life Disease
The large-scale study could help to target new ways of preventing and treating these diseases.
Genes Underlying Dogs’ Social Ability Revealed
The social ability of dogs is affected by genes that also seem to influence human behaviour, according to a new study from Linköping University in Sweden.
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
Programmable T cells shown to be versatile, precise, and powerful in lab studies.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
C Dots Show Powerful Tumor Killing Effect
Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!